| Tumor-specific cytolytic CD4 T cells mediate immunity against human cancer | Science Advances |  | | 2021 | 500 | 464 |
|
| Optimized combinatorial pMHC class II multimer labeling for precision immune monitoring of tumor-specific CD4 T cells in patients | Journal for immunotherapy of cancer | | | 2020 | 590 | 320 |
|
| High-throughput screening of human tumor antigen-specific CD4 T cells, including neoantigen-reactive T cells | Clinical Cancer Research |  | | 2019 | 456 | 4 |
|
| Vaccination of stage III/IV melanoma patients with long NY-ESO-1 peptide and CpG-B elicits robust CD8+ and CD4+ T-cell responses with multiple specificities including a novel DR7-restricted epitope | OncoImmunology | | | 2016 | 352 | 1 |
|
| Vaccination with long NY-ESO-1 79-108 peptide and CpG-B leads to robust activation of CD4 and CD8 T cell responses in stage III/IV melanoma patients, and a new HLA-DR7 epitope | 30th Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2015) | | | 2015 | 5 | 15 |
|
